Opportunities
•Portable, smartphone-enabled ophthalmometers priced <US$6 k are unlocking screening programs in India, Brazil, and Indonesia; combined with subscription-based tele-interpretation, vendors can tap a cumulative 45 million rural patients outside the traditional capital-equipment growth forecast horizon, expanding TAM by at least US$180 million before 2027.
•AI-driven keratoconus risk-scoring modules—cleared in South Korea and pending FDA 510(k)—create a differentiated software upsell (~US$300 per month per seat), lifting blended gross margins above 65 % and deepening switching costs for high-volume refractive chains.